

Supplemental information

Charlotte V. Rigby^{1,2,3,\$}, Dovile Juozapaite^{4,\$}, Ingrida Olendraite^{1,4}, Pankaj Mathur⁵, Kalyan Dhanorkar⁵, Vishalraj Hulle⁵, Tejas Shah⁶, Vijeta Jadhao⁶, Shravan Mutha⁶, Hamid Jalal³, Vikram Gopal^{5*}, Aartjan J.W. te Velthuis^{1,2,*}

¹ Lewis Thomas Laboratory, Department of Molecular Biology, University of Princeton, Princeton, 08540 NJ, United States.

² University of Cambridge, Department of Pathology, Addenbrooke's Hospital, Cambridge CB2 2QQ, United Kingdom.

³ Public Health England, Addenbrooke's Hospital, Cambridge CB2 2QQ, United Kingdom.

⁴ Vilnius University Hospital Santaros Klinikos, Hematology, Oncology and Transfusion Medicine Center, Santariskiu st. 2, 08661 Vilnius, Lithuania

⁵ Pune Instrumentation Pvt. Ltd., PCNTDA, Bhosari, Pune, 411026, India.

⁶ Krsnaa Diagnostics Ltd, Chinchwad, Pune, 411033, India

* Address correspondence to: VGopal@umich.edu; aj.te.velthuis@princeton.edu;

^{\$}contributed equally

Table S1. Clinical Ct values of samples used for Fig. 4A.

CoviPath 1-step multiplex kit		
Sample ID	Target	Ct
1	N	17.7
	ORF1ab	16.91
2	N	19.27
	ORF1ab	19.27
3	N	14.97
	ORF1ab	14.11
4	N	13.74
	ORF1ab	13.17
5	N	13.55
	ORF1ab	14.72
6	N	18.16
	ORF1ab	18.98
7	N	19.01
	ORF1ab	18.85
8	N	16.25
	ORF1ab	16.66
9	N	16.39
	ORF1ab	17.41
10	N	21.14
	ORF1ab	21.37

Table S2. Ct values of samples takes <5 days after onset of symptoms. Samples 3-6 were excluded from Fig. 1 and statistical analysis because of mismatched probes.

Sample ID	oligodT ₂₀ primer		Random hexamers	
	Target (probe)	Ct	Target (probe)	Ct
1	N (TaqPath)	19.3	N (TaqPath)	15.2
	ORF1ab (TaqPath)	20.3	ORF1ab (TaqPath)	16.0
2	N (TaqPath)	24.7	N (TaqPath)	23.3
	ORF1ab (TaqPath)	26.0	ORF1ab (TaqPath)	22.0
3	N (TaqPath)	22.8	N (LifeRiver)	20.8
	ORF1ab (TaqPath)	23.7	ORF1ab (LifeRiver)	20.9
4	N (TaqPath)	14.9	N (GeneXpert)	14.8
	ORF1ab (TaqPath)	15.9	E (GeneXpert)	12.4
5	N (TaqPath)	25.3	N (GeneXpert)	24.5
	ORF1ab (TaqPath)	25.9	E (GeneXpert)	22.6
6	N (TaqPath)	24.6	N (GeneXpert)	23.9
	ORF1ab (TaqPath)	25.9	E (GeneXpert)	22.1
7	N (TaqPath)	20.3	N (TaqPath)	18.3
	ORF1ab (TaqPath)	22.0	ORF1ab (TaqPath)	17.4
8	N (TaqPath)	21.3	N (TaqPath)	20.3
	ORF1ab (TaqPath)	22.8	ORF1ab (TaqPath)	21.6
9	N (TaqPath)	15.9	N (TaqPath)	18.1
	ORF1ab (TaqPath)	16.9	ORF1ab (TaqPath)	16.6
10	N (TaqPath)	24.6	N (TaqPath)	19.1
	ORF1ab (TaqPath)	25.6	ORF1ab (TaqPath)	18.8

Table S3. Ct values of samples takes >15 days after onset of symptoms. Undetectable levels are indicated with U.D.

Sample ID	oligodT ₂₀ primer		Random hexamers	
	Target (probe)	Ct	Target (probe)	Ct
1	N (TaqPath)	UD	N (TaqPath)	33.0
	ORF1ab (TaqPath)	UD	ORF1ab (TaqPath)	32.5
2	N (TaqPath)	UD	N (TaqPath)	32.8
	ORF1ab (TaqPath)	UD	ORF1ab (TaqPath)	33.8
3	N (TaqPath)	37.7	N (TaqPath)	31.7
	ORF1ab (TaqPath)	UD	ORF1ab (TaqPath)	33.3
4	N (TaqPath)	30.0	N (TaqPath)	32.1
	ORF1ab (TaqPath)	31.3	ORF1ab (TaqPath)	33.1
5	N (TaqPath)	34.2	N (TaqPath)	32.3
	ORF1ab (TaqPath)	37.8	ORF1ab (TaqPath)	32.1
6	N (TaqPath)	UD	N (TaqPath)	31.3
	ORF1ab (TaqPath)	UD	ORF1ab (TaqPath)	31.7
7	N (TaqPath)	UD	N (TaqPath)	37.8
	ORF1ab (TaqPath)	UD	ORF1ab (TaqPath)	37.3
8	N (TaqPath)	UD	N (TaqPath)	36.2
	ORF1ab (TaqPath)	UD	ORF1ab (TaqPath)	34.9
9	N (TaqPath)	UD	N (TaqPath)	34.0
	ORF1ab (TaqPath)	UD	ORF1ab (TaqPath)	UD
10	N (TaqPath)	UD	N (TaqPath)	33.1
	ORF1ab (TaqPath)	UD	ORF1ab (TaqPath)	34.2